Zevra Therapeutics
ZVRA
26 hedge funds and large institutions have $19.5M invested in Zevra Therapeutics in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 7 closing their positions.
13% less funds holding
Funds holding: 30 → 26 (-4)
17% less capital invested
Capital invested by funds: $23.4M → $19.5M (-$3.91M)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DA
DSC Advisors
Chicago,
Illinois
|
+$1.11M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$184K |
| 3 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$179K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$59K |
| 5 |
VF
Virtu Financial
New York
|
+$48.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$2.82M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$640K |
| 3 |
PL
Parkwood LLC
Cleveland,
Ohio
|
-$503K |
| 4 |
NWM
Northwest Wealth Management
Spencer,
Iowa
|
-$83K |
| 5 |
Goldman Sachs
New York
|
-$71K |
ZVRA Hedge Fund Activity: Q3 2017 in Review
26 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q3 2017, worth a combined $19.5M — down 17% from $23.4M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ZVRA and 3 opened new positions — a net loss of 4 holders — while 9 trimmed existing stakes and 6 added.
The largest buyer was DSC Advisors, adding an estimated $1.11M. The largest seller was Deerfield Management, exiting entirely with an estimated $2.82M sold.
- 26 institutional investors held Zevra Therapeutics (ZVRA) as of Q3 2017, down from 30 in Q2 2017.
- Funds reported $19.5M of Zevra Therapeutics stock for Q3 2017, down 17% quarter-over-quarter.
- 3 funds opened new Zevra Therapeutics positions in Q3 2017 and 7 closed out, a net change of -4 holders.
- The largest Zevra Therapeutics buyer in Q3 2017 was DSC Advisors, an estimated $1.11M added.
- The largest Zevra Therapeutics seller in Q3 2017 was Deerfield Management, an estimated $2.82M sold.
Based on aggregated 13F filings for Q3 2017.